A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA

Table 4

Mean change from baseline in total WOMAC.

Visits	Curene® 500mg		Placebo
	N=25		N=25
	Mean (SD)	Change from baseline	Mean (SD)	Change from baseline
Baseline (Day 0)	37.88±4.14		37.36±4.08
Visit 2 (Day 7)	34.88±5.27	3±1.55	36.4±3.88	0.96±1.77
Visit 3 (Day 15)	31.44±4.85	6.44±1.50	34.36±3.79	3±2.22
Visit 4 (Day 30)	25.84±5.54	12.04±2.89	32.76±3.88	4.6±2.81
Visit 5 (Day 60)	18.44±4.75	19.44±3.74	30.76±4.84	6.6±3.66

Statistically significant (P <0.05) within group; ∧ statistically significant (P <0.05) between group.
Within group analysis by Pair t-test and between group analysis by repeated measures ANCOVA.